Marc Hedrick, President & CEO of Plus Therapeutics PSTV, recently presented at Benzinga's Virtual HealthCare Summit 2024.
Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company is currently targeting glioblastoma (GBM) and leptomeningeal metastases (LM), two of the most aggressive forms of cancer.
The goal of the company is to make difficult cancers like GBM more like chronic cancers like melanoma.
Learn more here
Featured photo by National Cancer Institute on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
